Related Experiment Video

Updated: Mar 19, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K

Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and

Theresa M LaVallee1, Diego Alvarado1, Andrew J Garton1

  • 1Kolltan Pharmaceuticals, Inc., New Haven, CT.

Critical Reviews in Oncogenesis
|June 10, 2016
PubMed

Insights

Receptor tyrosine kinases (RTKs) are crucial for cell biology and successful drug targets in cancer and inflammatory diseases. This review highlights RTKs in cancer therapy, immunity, and potential non-oncology applications.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinases regulate fundamental cellular processes.
  • Receptor tyrosine kinases (RTKs) are a key class of protein kinases, with 58 members, extensively studied in development and cancer.
  • Targeting RTKs has yielded numerous drugs for various cancers and inflammatory conditions.

Purpose of the Study:

  • To review the clinical benefits of targeting specific RTKs in cancer, focusing on the ErbB family (EGFR, HER2, ErbB3) and KIT.
  • To discuss the emerging role of RTKs in regulating innate immunity.
  • To explore the potential of targeting RTKs beyond oncology.

Main Methods:

  • Literature review of RTKs in cancer therapy.
  • Analysis of RTK involvement in innate immunity.
  • Exploration of non-oncology therapeutic applications of RTKs.

Main Results:

  • Drugs targeting ErbB family members (EGFR, HER2, ErbB3) and KIT have shown significant clinical efficacy in various cancers.
  • RTKs play an increasingly recognized role in the regulation of innate immune responses.
  • There is potential for developing RTK-targeted therapies for diseases outside of cancer.

Conclusions:

  • RTK-targeting therapies have transformed cancer treatment and show promise in other diseases.
  • Understanding RTK roles in immunity opens new therapeutic avenues.
  • Further research into non-oncology RTK targets is warranted.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

8.1K

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K